GLP-1s across the District's own health programs
The District runs more than one health program and they do not give the same answer. The Health Care Alliance, paid for out of local funds, rules out anti-obesity medications in a sentence that closes the medical-necessity route as well. The plan bought for District employees covers Mounjaro, Ozempic and Rybelsus, each with a notification requirement attached, and lists nothing approved for weight. The District's Medicaid drug list is not described here at all: it sits on a host that answered 200 for a made-up address, so nothing on it can be verified by fetching.
What changed, and what the document says
What the Alliance will not pay for
Not coveredThe exclusion is absolute on its face, and the clause about medical necessity is part of it rather than an exception to it.
“No coverage, branded or generic, and even if deemed medically necessary, for: • Anti-obesity medications”
Government of the District of Columbia, Department of Health Care Finance (DHCF) — Version 1.0 (9/9/25)
What it does pay for
Conditions applyA named, limited generic formulary, administered by a pharmacy benefit manager rather than by the agency.
“A limited number of generic prescription medications are covered. Please refer the Prime Limited Alliance Formulary.”
Government of the District of Columbia, Department of Health Care Finance (DHCF) — Version 1.0 (9/9/25)
What it costs at the counter
CoveredFor the medicines that are on that formulary, nothing. The barrier here is the list, not the price.
“There are no premiums and no copayments or other charges for medical services covered by Health Care Alliance. There is a zero ($0) dollar copay for prescriptions.”
Government of the District of Columbia, Department of Health Care Finance (DHCF) — Version 1.0 (9/9/25)
Generic only, from January
Conditions applyA brand-name prescription stopped being reimbursable for Alliance patients on the first day of 2026.
“Beginning on this date, coverage for prescription medications will continue to be generic-only formulations where an FDA-approved generic equivalent is available.”
Government of the District of Columbia, Department of Health Care Finance — Office of the Senior Deputy Director and Medicaid Director — December 29, 2025
The three ways past it
ContextThe transmittal names them: no generic exists, the drug is on an exception list, or a medical-necessity request is approved.
“Brand-name medications will no longer be reimbursed unless a generic alternative is unavailable, the medication is on the exception list, or a medical necessity exception is approved.”
Government of the District of Columbia, Department of Health Care Finance — Office of the Senior Deputy Director and Medicaid Director — December 29, 2025
What the letters mean on the employees' list
Conditions applyMounjaro, Ozempic and Rybelsus each appear on the 2026 District employees' list carrying both markers — a notification before coverage is decided, and a ceiling on how much is dispensed.
“Quantity limits — The largest quantity of medication covered per copayment or in a defined period of time.”
UnitedHealthcare, published by the DC Department of Human Resources (DCHR) — Effective January 1, 2026
Who writes that list
ContextNot the District. The employees' drug list is published by its human resources department but decided by the insurer's own committee.
“The UnitedHealthcare® Pharmacy and Therapeutics Committee, which includes both internal and external doctors and pharmacists, meets regularly to provide clinical reviews of all medications.”
UnitedHealthcare, published by the DC Department of Human Resources (DCHR) — Effective January 1, 2026
What the District didn't publish
The 2026 drug list published for District government employees contains no medication approved for weight management, and does not print the word weight anywhere.
We looked at 90 documents to say that — all 90 pages of the 2026 DC Government Employees Prescription Drug List, converted to text and read end to end.
The identical scan, in the same run, found Ozempic 4 times, Mounjaro twice, Rybelsus twice, Trulicity twice and liraglutide twice — the ruler finds GLP-1 brand names in this document, which is the same kind of token Wegovy and Zepbound are. Against those same 90 pages, Wegovy, Zepbound, Saxenda, obesity, anti-obesity, appetite and weight each returned zero.
Checked September 2026 against Your 2026 Prescription Drug List — DC Government Employees, UnitedHealthcare, published by the DC Department of Human Resources (DCHR).
Which of these companies serve the District of Columbia?
Of the 257 companies we grade, 25 publish a list of the states they are licensed in. We checked 229 more and found no such list on any page we read; 3 we have not checked either way.
8 of those lists name the District of Columbia: Vita Bella, TelePeptide, Wisp, Ways2Well, Trimi, Enhance MD, HumeCare+ and Mojoon. That is a licensure claim each company makes about itself, not something we checked with a state board.
A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.
Sources
Each document below was fetched and read on the date shown beside it, which is the date printed on the document — not always the date in its web address. All of them were read in September 2026, the same session as the rest of this page.
- Alliance and ICP Program Changes Effective October 1, 2025 — Government of the District of Columbia, Department of Health Care Finance (DHCF). the version stamp printed at the foot of every page: Version 1.0 (9/9/25).
- Transmittal 25-37 — Important Update Healthcare Alliance: Transition to Generic-Only Prescribing Effective January 1, 2026 — Government of the District of Columbia, Department of Health Care Finance — Office of the Senior Deputy Director and Medicaid Director. the "DATE:" line in the transmittal's own header block: December 29, 2025.
- Your 2026 Prescription Drug List — DC Government Employees — UnitedHealthcare, published by the DC Department of Human Resources (DCHR). printed on the cover, beside the sentence "This Prescription Drug List (PDL) is accurate as of January 1, 2026": Effective January 1, 2026.
Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.
If you're paying cash instead
None of the above changes what a telehealth seller charges you. 1 of these 3 bills a fee every month on top of the medication, so the figure is the two added together. The other 2 say in the cell what we could capture and what we could not. Every number was read on the seller's own page; the adding up is ours.
1 of these 3 pays us a commission if you start there: Found. Rx.com and Hims pay us nothing. A commission never changes a grade.
| Grade | Provider | What a month actually costs | The one thing that matters here | Go to the provider |
|---|---|---|---|---|
| BMinor gap | Found | $289a month, medication onlycompounded semaglutide, cash pay, month to monthMedication only. We captured no separate monthly charge on the pages we read, which is what we found rather than proof that nothing else is billed.Cash pay, month to month, after a $179 first month. $169 is the twelve-month rate. Found bills every 28 days, and the price includes the medication, the clinician and the membership.The lowest of the 2 medication prices we captured here | Publishes its whole ladder in its own offer terms and every figure is all-in — compounded semaglutide at $289 a month paying month to month, $169 on a twelve-month plan — which is a readable cash number where a formulary gives none. | See its prices at Found (opens in a new tab)Pays us a commission |
| BMinor gap | Rx.com | $175a month, medication onlycompounded semaglutideMedication only. We captured no separate monthly charge on the pages we read, which is what we found rather than proof that nothing else is billed.One month, all-in: the visit, the medication at any dose, supplies and cold shipping. The $146 headline is the six-month plan, paid as $875 in one payment.The lowest of the 2 medication prices we captured here | Prices compounded semaglutide at $175 for one month and tirzepatide at $285, all-in, and its checkout showed the same $175 rather than a different one. | See its prices at Rx.com (opens in a new tab)Pays us nothing |
| CCaveat | Hims | $298a month, everything billed monthly$149 brand semaglutide + $149 a month for membershipThe Weight Loss Membership itself. It runs $39 the first month and renews at $149 a month, is billed separately from the medication, and Hims says medication is not available without it.This is the medication price for the Wegovy oral pill. Hims states on the same page that the figure covers medication only and that an active Weight Loss Membership, billed separately, is required.The lowest of the 4 medication prices we captured here | Its From $149/mo headline covers medication only, and the membership it says you cannot get medication without is disclosed in a footnote under the price grid. | See its prices at Hims (opens in a new tab)Pays us nothing |
Our grading method and how we verify a price explain what those letters mean and where these figures came from.